Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to assess the safety of semagacestat in Alzheimer’s disease patients during 24 months of open-label treatment following completion of up to 21 months of active treatment in a double-blind registration study (LFAN or LFBC) through analysis of AEs, vital signs, laboratory evaluations, and electrocardiograms (ECGs).
Critère d'inclusion
- Alzheimer's disease